Psychedelics - Spark Newswire

2 minute read

atai Life Sciences: Unparalleled Diversification With 10 Psychedelic Compounds Going Into Clinical Trials In 2022

May 26, 2:10 PM

In the speculative world of ‘psychedelic’ biotech, companies that are under-capitalized or lacking pipeline diversity face an uphill battle to reach the finish line.

ATAI

2 minute read

High Hopes For Alcohol Use Disorder Treatment: Clearmind’s Successful Pre-IND Meeting With The FDA

By Lara Goldstein

May 26, 1:37 PM

The meeting, which took place on May 18 between the psychedelic pharmaceutical biotech company Clearmind Medicine Inc. (CMNDF) and the US Food and Drug Administration marks the completion the pre-IND New Drug Application stage.

CMNDF

1 minute read

Optimi Completes First Grow of Psilocybin Mushrooms, Introduces New Head Of Cultivation

By Lara Goldstein

May 25, 1:31 PM

Optimi Health Corp. (OPTHF), the Canadian company that produces homegrown and scalable mushrooms accessible to all, announces big step towards commercialization. It has successfully completed its first batch of psilocybin cubensis and functional mushrooms and is ready for supply agreements and direct work with physicians.

OPTHF

6 minute read

Psyched: Medical Psychedelics In Davos, Canadian Sen Does Psychedelics, Ei.Ventures & Mycotopia To Merge Into $383M Company

By Natan Ponieman

May 24, 8:52 PM

Medical Psychedelics have made it into Davos, just in time for the World Economic Forum.

AWKNF

2 minute read

Psychedelic Treatment For Alcoholism? Clearmind Medicine And SciSparc Collaboration Yields Positive Results

By Vuk Zdinjak

May 24, 10:55 AM

Clearmind Medicine Inc. (OTCPK:CMNDF) (CSE:CMND) (FSE:CWY0) a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, revealed positive safety profile results from its joint pre-clinical trial with SciSparc Ltd.

CMNDF

3 minute read

Christian Angermayer Bullish On Psychedelic Sector And Life Extension Technology

By The Dales Report

May 23, 12:26 PM

In this week’s Trade To Black Podcast, TDR Founder Shadd Dales and lead financial writer Benjamin A. Smith interview the founder of Apeiron Investment Group, Christian Angermayer.

ATAI

1 minute read

MindMed Appoints Schond L. Greenway As CFO

By Vuk Zdinjak

May 23, 11:38 AM

Mind Medicine Inc. (NASDAQ: MNMD), (NEO:MMED), a clinical stage bio-pharmaceutical company developing novel products to treat brain health disorders, appointed Schond L. Greenway as CFO.

AVTX